Bimetinib tablets 15mg/tablet, 180 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Cardiomyopathy: left ventricular ejection fraction (LVEF) is assessed before starting treatment, one month after treatment, and every 2 to 3 months thereafter. The safety of LuciBinim in patients with an LVEF lower than 50% has not been determined.
• Venous thromboembolism: Deep vein thrombosis and pulmonary embolism may occur.
• Ocular toxicity: serous retinopathy, retinal vein occlusion (RVO), and uveitis have occurred. Perform regular eye assessments and check for any visual impairments.
• Interstitial lung disease (ILD): Evaluate for new or progressive unexplained pulmonary symptoms to determine if ILD may be present.
• Hepatotoxicity: Monitor liver function before and during treatment and as clinically indicated.
• Rhabdomyolysis: Monitor creatine phosphokinase and creatinine regularly and as clinically indicated.
• Bleeding: Serious bleeding events may occur.
• Embryo-fetal toxicity: May cause harm to the fetus. Women of childbearing potential are advised to be aware of the potential risks to the fetus and to use effective contraception.

Medication risks

Adverse Reactions
The most common adverse effects (≥ 25%) of LuciBinim in combination with Encorafenib are fatigue, nausea, diarrhea, vomiting, and abdominal pain.